Streetbeat News

TCBP

TC Biopharm (Holdings) Plc

https://www.tcbiopharm.com

Industry

Biotechnology

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Open

0.60

Mkt cap

13K

Volume

330K

High

0.60

P/E Ratio

N/A

52-wk high

41.50

Low

0.49

Div yield

N/A

52-wk low

0.44

TC BioPharm partners with CareDx to use AlloCell for pharmacokinetic monitoring in the ACHIEVE clinical trial, focusing on allogeneic gamma-delta T cell therapies for AML and MDS.

Portfolio Pulse from

December 11, 2024 | 12:15 pm

TC BioPharm (NASDAQ: TCBP) announced a positive update on their ACHIEVE UK clinical trial, with promising safety data allowing for higher doses of TCB008. The trial is progressing with four UK sites recruiting patients and two more expected by H1 2025.

Portfolio Pulse from

December 04, 2024 | 1:45 pm

TC BioPharm (NASDAQ: TCBP) has received $250,000 in non-dilutive funding from the G-Rex® Grant Program, a $20M initiative by ScaleReady, Wilson Wolf Manufacturing, and Bio-Techne Corporation to advance cell and gene-modified cell therapy development.

Portfolio Pulse from

November 12, 2024 | 2:45 pm

TC BioPharm has announced the signing of two non-binding letters of intent for acquisitions in cell therapy modalities outside its core TCB008. This move indicates a strategic expansion beyond its current focus.